OCSAW Stock Price & Analysis — Oculis Holding AG Warrants (Healthcare >> Biotechnology)
OCSAW FAQ
What is OCSAW's ROE?
Oculis Holding AG Warrants reports a Return on Equity (ROE) of -48.10%.
What is OCSAW's dividend yield?
Oculis Holding AG Warrants offers a dividend yield of 0.00%.
What is OCSAW's Quality Score?
Our AI rates OCSAW's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy OCSAW?
Our AI Timing Score for OCSAW is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does OCSAW belong to?
Oculis Holding AG Warrants is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
OCSAW AI Analysis Summary
Our AI summary for OCSAW: Oculis Holding AG Warrants (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -48.10%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 0/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 4.50
Price
0.67
(17.49%)
Day Change
|
|
|---|
OCSAW, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 4.50 |
| PBV / Sector |
N/A / 44,105.10
|
| Earning Per Share | N/A |
| PE / Sector |
N/A / 19.37
|
| PEG or PE/Growth / Sector |
N/A / 1.06
|
| Average 1M Daily Value |
0.02 M
GREAT
|
| Average 1W Daily Value |
0.01 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-06 08:00:26 |
| Symbol | OCSAW |
| Name | OCULIS HOLDING AG WARRANTS |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 0.00 |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | N/A / 9,702.21 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Description: Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. Its product candidates in development includes OCS-01, a topical retinal candidate for diabetic macular edema; OCS-02, a topical biologic candidate for dry eye disease; and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap
Google